Formula Optimization of NLC with D-Mannose Targeting for Rifampicin Delivery System
Abstract
Limited accumulation of anti-tuberculosis drugs in macrophages become a barrier to the success of latent tuberculosis therapy. The purpose of this study is to develop a D-mannose modified nanoparticle formula as a targeting agent to the mannose receptors to increase the internalization of rifampicin into macrophages. D-mannose was conjugated with chitosan using an amine reducing agent. Chitosan-D-mannose conjugate was characterized using FTIR. Subsequently, the conjugate was adsorbed onto the nanostructured lipid carrier (NLC) electrostatically. The NLC formula consisted of an ethyl acetate solution of solid-liquid lipid blend and rifampicin and an aqueous solution of chitosan-D-mannose conjugate, which were emulsified using polysorbate 80. Solidification of the NLC-chitosan-mannose nanoparticles was carried out by ionotropic gelation and solvent evaporation. The nanoparticle formula was optimized using Box-Behnken design. The formation of chitosan-D-mannose conjugate was shown by the change of the amide band wave number and the Schiff base formation of the FTIR spectra. The optimum formula of nanoparticles had a diameter of 766.1 ± 57.56 nm with a polydispersity index of 0.32 ± 0.02, encapsulation efficiency of 91.54 ± 0.18% and drug loading of 36.62 ± 0.07%. Rifampicin was released from the nanoparticles at pH 5.2 or 7.4 with a similar rate. This D-mannose modified NLC formula has the potential to be further developed as an intracellular antibiotic targeting to macrophages.
References
2. Kang PB, Azad AK, Torrelles JB, Kaufman TM, Beharka A, Tibesar E & Schlesinger LS. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. Journal of Experimental Medicine. 2005. 202(7): 987-999.
3. Torrelles JB, & Schlesinger LS. Diversity in Mycobacterium tuberculosis mannosylated cell wall determinants impacts adaptation to the host. Tuberculosis. 2010. 90(2): 84-93
4. World Health Organization. Global tuberculosis report 2015. 2015.
5. Becker C. Preparation of biowaiver recommendations for antituberculosis drugs [dissertation]. Senckenberg: Universitätsbibliothek Johann Christian. 2009.
6. Pardeike J, Hommoss A, & Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. International journal of pharmaceutics. 2009. 366(1): 170-184
7. Naseri N, Valizadeh H, & Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Advanced pharmaceutical bulletin. 2015. 5(3): 305.
8. Yang X, Patel S, Sheng Y, Pal D., & Mitra AK. Statistical design for formulation optimization of hydrocortisone butyrate-loaded PLGA nanoparticles. AAPS PharmSciTech. 2014. 15(3): 569-587.
9. Chaubey P, & Mishra B. Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis. Carbohydrate polymers. 2014. 101: 1101-1108.
10. Gribble GW & Ferguson DC. Reactions of sodium borohydride in acidic media. Selective reduction of aldehydes with sodium triacetoxyborohydride. Journal of the Chemical Society, Chemical Communications. 1975. (13): 535-536.
11. Nkuzinna OC, Menkiti MC, Onukwuli OD, Mbah GO, Okolo BI, & Egbujor MC. Application of Factorial Design of Experiment for Optimization of Inhibition Effect of Acid Extract of Gnetum africana on Copper Corrosion. Natural Resources. 2014. 5(07): 299.
12. Trinh TK & Kang LS. Application of response surface method as an experimental design to optimize coagulation tests. Environmental Engineering Research. 2010. 15(2): 63-70.
13. Montgomery DC. Design and Analysis of Experiments. 4th Wiley. New York; 1997. p. 704.
14. McCarron PA, Woolfson AD, & Keating SM. Response surface methodology as a predictive tool for determining the effects of preparation conditions on the physicochemical properties of poly (isobutylcyanoacrylate) nanoparticles. International journal of pharmaceutics. 1999. 193(1): 37-47.
15. Hirota K & Terada H. Endocytosis of particle formulations by macrophages and its application to clinical treatment. In Molecular Regulation of Endocytosis. InTech. 2012.
16. Pinheiro M, Ribeiro R, Vieira A, Andrade F, & Reis S. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug design, development and therapy. 2016. 10:2467.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.